Similarly, a bispecific antibody targeting Siglec-15 (S15) and TGF-β leverages tumor-specific S15 expression to localize TGF-β inhibition, synergistically overcoming immunosuppression and remodeling the tumor immune microenvironment [80]. This evidence concerns the gene TGFB1 and neoplasm.